MKULQ — Molekule Income Statement
0.000.00%
- $0.01m
- $30.91m
- $0.23m
Annual income statement for Molekule, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0.617 | 0.227 |
Cost of Revenue | ||||
Gross Profit | — | — | 0.278 | 0.115 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.153 | 3.32 | 8.86 | 6.9 |
Operating Profit | -0.153 | -3.32 | -8.24 | -6.67 |
Net Income Before Taxes | -0.153 | -3.32 | -8.24 | -6.67 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.153 | -3.32 | -7.92 | -6.17 |
Net Income Before Extraordinary Items | ||||
Extraordinary Items | ||||
Net Income | -0.153 | -3.32 | -7.92 | -6.17 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.153 | -3.32 | -7.92 | -6.17 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.013 | -0.292 | -0.742 | -0.416 |